ESMO26: Toni Choueiri, MD, on KEYNOTE-564 - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ESMO26: Toni Choueiri, MD, on KEYNOTE-564

  • November 17, 2026

Share

Objective:

The article examines the objective, findings, and clinical context described in ESMO26: Toni Choueiri, MD, on KEYNOTE-564.

Approach:
  • Follow-up: The final analysis was presented after 7 years of follow-up.
  • Treatment: The trial evaluated adjuvant pembrolizumab.
Key Findings:
  • After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival in high-risk clear-cell renal cell carcinoma.
  • After 7 years of follow-up, adjuvant pembrolizumab continued to extend overall survival in high-risk clear-cell renal cell carcinoma.
Interpretation:

The final analysis of KEYNOTE-564 found that adjuvant pembrolizumab continued to extend disease-free and overall survival in high-risk clear-cell renal cell carcinoma.

Limitations:
  • The provided context does not include numerical results, study methods, or details about adverse events.
Sources:

Original Source(s)

Related Content